Results 71 to 80 of about 3,738,036 (312)
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
A Classification Method for General Medicine Physicians to Advance Field Research in Japan
Masaki Tago,1 Risa Hirata,1 Kiyoshi Shikino,2,3 Takashi Watari,4 Hiromizu Takahashi,5 Tomoyo Nishi,1 Yosuke Sasaki,6 Taro Shimizu7 1Department of General Medicine, Saga University Hospital, Saga, Japan; 2Department of Community-Oriented Medical Education,
Tago M +7 more
doaj
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
[What (general/abdominal) surgeons should know about occupational medicine? : General vaccine recommendations and postexposure prophylaxis of hepatitis B, C and HIV]. [PDF]
Thielmann B, Meyer F, Böckelmann I.
europepmc +1 more source
Editorial: Methods in general cardiovascular medicine
Serafino Fazio +4 more
doaj +1 more source
BACKGROUND AND OBJECTIVE: Doing and writing the qualified thesis could be considered as the onset of the research proceeding and formation of academic identity of students.
Mohammad rasoul Khazaee +3 more
doaj
Rapid weight gain after PEG placement can precipitate Buried Bumper Syndrome (BBS) by increasing abdominal wall thickness, even in nonobese patients. Regular reassessment of external bumper position and tube length is essential in patients expected to ...
Satoshi Inaba +5 more
doaj +1 more source
Approach to the patient with metabolic syndrome in general medicine [PDF]
Miloranka Petrov-Kiurski
openalex +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source

